

# Halozyme Therapeutics, Inc.

## ENHANZE<sup>®</sup> Royalty Summary

NASDAQ: HALO

March 2025

## Forward-Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and expectations for future total revenues. Forward-looking statements also include anticipated new patent grants (including the potential U.S. reissue grant referred to in this presentation), patent expiration dates, and royalty terms and rates for the Company's current ENHANZE<sup>®</sup> collaboration products and product candidates, and the potential for the Company's existing and potential additional patents and co-formulation patents to extend royalty payment periods and maintain royalty rates. These forward-looking statements are typically, but not always, identified through use of the words "expect," "project," "may," "will," "could," "can," "durable," "growth," "innovate," "develop," "vision," "potential," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations

contained in these forward-looking statements as a result of several factors, including unexpected early expiration or termination of the patent and coformulation patent terms referred to in this presentation for the Company's ENHANZE<sup>®</sup> drug delivery technology, unexpected levels of revenues (including royalty revenue received from our collaboration partners), unexpected delays in obtaining new co-formulation or proprietary intellectual property, or in the development, regulatory review or commercialization of our partners' ENHANZE<sup>®</sup> products. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The Company undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

# Licensed Partner Products

## Anticipated Royalty Terms and Rates for Select Products

Product Name	Co-Formulation Patent Status & Anticipated Impact	First Commercial Sale	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2040	
Herceptin SC	Granted (royalty to expiry 07/2030)		[Green bar from 2023 to 2030]														
Mabthera SC	Granted (royalty to expiry 09/2030)		[Green bar from 2023 to 2030]														
Phesgo	Granted (royalty to expiry 07/2030)		[Green bar from 2023 to 2030]														
Darzalex Faspro/SC	Granted (royalty 12 years post first commercial sale)		U.S./ROW							[Light blue bar from 2029 to 2032]				U.S. mid-single digit to 2029 possible with U.S. reissue grant*			
			Europe							[Light blue bar from 2029 to 2032]							
HyQvia 10%	Granted (royalty to expiry 09/2030)		[Green bar from 2023 to 2030]														
Tecentriq SC	Pending (if patent granted, royalties to 12/2040)		[Green bar from 2024 to 2040]														
Ocrelizumab SC	10-year term; no royalty reduction through 9/2030 if pending patent granted		[Green bar from 2024 to 2030], [Light blue bar from 2030 to 2035]														
VYVGART Hytrulo	Pending (if patent(s) granted, royalties to 2040s)		[Green bar from 2024 to 2029], [Light blue bar from 2029 to 2040]														

■ Mid-single digit royalty rate
 ■ Reduced royalty rate

Royalty terms are estimated based on earliest co-form filing date and assumes at least one valid, granted patent. Amivantamab SC and Nivolumab SC not included, because consent to display information for those products not obtained from the licensees. Except for Darzalex SC and Darzalex Faspro, does not account for non-public (un-published) pending co-form applications. \* Assumes claims of granted ENHANZE reissue patent have same scope as related European product-by-process patent.